Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-10-07
B
Bailu Peng
Role not yet determined Is this you? Add your title
Also affiliated: The University of Texas MD Anderson Cancer Center (2002–2009); Southern Medical University (2013); The University of Texas Health Science Center at Houston (2004)
18 h-index
28 pubs
2,512 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Bailu Peng's research focuses on the molecular mechanisms underlying cellular signaling pathways, particularly the role of NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) in various biological processes. Peng has investigated how NF-κB activation is regulated by upstream signaling molecules, such as IKK2/β, IL-1α, and p62, and its involvement in the development of diseases like pancreatic ductal adenocarcinoma. Further research has explored the interplay between NF-κB and other transcription factors, including AP-1, and its influence on gene expression and cellular functions like apoptosis and cell migration. Peng's work also examines the expression of embryonic stem cell markers and their correlation with epithelial-mesenchymal transition in nasopharyngeal carcinoma. With an h-index of 18 and over 2,500 citations across 29 publications, Peng has collaborated with researchers including Fenghuang Zhan, Guido Tricot, John D. Shaughnessy, and Yan Cheng at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 18
- Publications: 28
- Citations: 2,512
Selected Publications
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
-
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021)
-
Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma (2021)
-
CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction (2020)
Collaboration Network
Top Collaborators
Frits van Rhee
Winthrop Rockefeller Foundation
5 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Dongzheng Gai
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Guido J. K. Tricot
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
John D. Shaughnessy
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Fumou Sun
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Yan Cheng
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Hongwei Xu
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Jin‐Ran Chen
Arkansas Children's Nutrition Center
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Maurizio Zangari
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Fenghuang Zhan
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Siegfried Janz
Medical College of Wisconsin (US)
3 shared publications
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Can Li
Central South University (CN)
2 shared publications
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction
Huojun Cao
University of Iowa (US)
2 shared publications
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Intawat Nookaew
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Cody Ashby
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Similar Researchers
Based on overlapping research topics
Nora Gibbons
University of Arkansas for Medical Sciences
Disease Models, Animal
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Yejin Kim
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Models, Animal
Immune Response and Inflammation
Abhishek Mishra
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Models, Animal
Immune Response and Inflammation
Yu‐Jin Jeong
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Models, Animal
Receptor Mechanisms and Signaling
Shengyu Mu
University of Arkansas for Medical Sciences
Disease Models, Animal
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Nathaniel L. Harris
University of Arkansas at Fayetteville
Disease Models, Animal
Immune Response and Inflammation
Receptor Mechanisms and Signaling